Validation gaps in Medicine

Representative open questions

Showing 30 of 591 — one per source paper, highest-quality first.

• Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation (2026) · doi

  The EIGHT Treg study lacks a control group for conventional induction immunosuppression, making it difficult to assess the efficacy of CD8+ Tregs in preventing renal graft rejection.

• Heart-brain axis pathophysiological understanding and clinical impact (2026) · doi

  High-sensitivity cardiac troponin T elevation in acute ischemic stroke patients (references 109, 114, 118) lacks standardized predictive thresholds and timing protocols; prospective studies defining optimal troponin measurement intervals and cutoff values for identifying neurogenic cardiac injury are needed.

• The impact of traumatic injury on the respiratory system; a narrative review of injury-associated and clinically-induced mechanisms of trauma-associated pneumonia (2026) · doi

  Machine learning approaches have been applied to predict pneumonia in flail chest patients, but external validation of these predictive models across different trauma populations and prospective testing in clinical practice settings is lacking, limiting their generalizability and clinical utility.

• FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) – a randomized, open-label, multicenter phase II trial protocol (2026) · doi

  The synergistic effects of combining hypofractionated, accelerated dose delivery with target volume reduction in locally advanced NSCLC have not been directly quantified in randomized trials. The biologically effective dose calculations and their relationship to both acute/late toxicity reduction and immunotherapy advancement rates require prospective validation with organ-at-risk dose constraints.

• From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma (2026) · doi

  Organelle phenotypes must be systematically integrated with clinical features and patient outcomes in cHCC-CCA cohorts to establish whether organelle biology can predict treatment response and prognosis, enabling precision medicine approaches that match organelle-targeting agents to individual tumor biology.

• Managing Spinal Muscular Atrophy: A Look at the Biology and Treatment Strategies (2025) · doi

  SMN2 copy number and variants have been shown to modify SMA phenotype, but the genotype-phenotype correlations in patients with complex SMN2 structural variations and deletion junctions require larger cohort validation beyond existing studies to establish predictive biomarkers for disease progression.

• Integration of biomedical imaging and sensing technologies with AI-IoT for Materiovigilance and predictive modeling of stillbirth risk in maternal-fetal health monitoring (2026) · doi

  AI model generalization and repeatability are compromised by data heterogeneity across different sensor types, maternal conditions, and gestational stages. Longitudinal prospective cohort studies involving multiple populations are required to test AI-IoT algorithms and guarantee scalability across varied maternal-fetal monitoring scenarios.

• Neurosurgery as an immune anchor point: a translational framework for perioperative immunoengineering (2026) · doi

  The paper identifies meningeal immunity and neuroinflammation-associated neurotoxicity from immune checkpoint inhibitor therapy but does not specify mechanistic predictors for identifying patients at high risk of severe neurological adverse events. Biomarker profiling of clonally expanded effector CD4+ cytotoxic T lymphocytes and their correlation with perioperative autonomic nervous system imbalance requires prospective validation in neurosurgical cohorts.

• The neuro-immune axis in preeclampsia: from the maternal-fetal interface to systemic dysregulation (2026) · doi

  The paper identifies that different preeclampsia subtypes (acute neurovascular instability versus placental angiogenic dysfunction) should exhibit distinct autonomic imbalance signatures, but does not specify which standardized autonomic biomarkers should be measured (heart rate variability indices, baroreceptor sensitivity, sympathetic/parasympathetic tone ratios) or establish cutoff thresholds for distinguishing PE subtypes.

• The use of artificial intelligence based modelling techniques in One Health-related infectious disease studies in Sub-Saharan Africa: a review (2026) · doi

  AI-based One Health infectious disease models in Sub-Saharan Africa currently lack systematic validation using external datasets from independent geographic regions within SSA; cross-validation and sensitivity analyses across West and Central African contexts remain largely absent from the literature.

• Autologous Platelet Concentrates in Sports Medicine: Mechanisms of Tissue Regeneration and Clinical Applications – A Narrative Review (2026) · doi

  High-quality clinical trials have not adequately validated the theoretical tissue-specific matching of leukocyte-rich versus leukocyte-poor PRP formulations in tendon versus intra-articular applications, nor have they demonstrated whether PRF and i-PRF's fibrin-based scaffold properties and slower growth factor release kinetics provide superior outcomes in chronic lesions or poorly vascularized tissues.

• What is The Effect of Early Enteral Nutrition on Mortality in Critically Ill Patients Receiving Vasopressor Support? : A Systematic Review (2026) · doi

  The paper documents inconsistent mortality outcomes across disease-specific cohorts (COVID-19 pneumonia showing benefits, septic shock showing variable results, ARDS and traumatic brain injury requiring tailored approaches), yet no comparative effectiveness trials have systematically evaluated organ-dysfunction-specific feeding strategies (dose, timing, route) to determine risk-benefit profiles for ARDS, acute pancreatitis, and traumatic brain injury patients on vasopressor support.

• Decision-ready evidence for vital pulp therapy: a network meta-analysis of bioactive materials in mature permanent teeth (2026) · doi

  The network meta-analysis stratified mature permanent teeth but did not separately analyze outcomes for specific tooth types (molars vs. premolars vs. incisors) or by caries depth/location, which may differentially affect hemostasis control and restoration margins in pulpotomy procedures. Future RCTs should report subgroup analyses of absolute success rates for bioactive materials disaggregated by tooth type and caries extent.

• Exercise benefits in metabolism on cardiovascular disease (2026) · doi

  Although extracellular vesicles have been shown to mediate tissue crosstalk during exercise, the specific composition and functional role of exercise-induced extracellular vesicles in improving cardiovascular metabolic outcomes across different cardiovascular disease phenotypes and exercise prescriptions requires systematic investigation.

• What is the diagnostic accuracy of different clinical diagnostic criteria (Rotterdam, NIH, and Androgen Excess Society) for identifying polycystic ovary syndrome in women of reproductive age? : A Systematic Review (2026) · doi

  Population-specific follicle count thresholds for PCOS diagnosis vary substantially across ethnic groups (Turkish women: 8 follicles, North African women: 18 follicles, Chinese adolescents: lower thresholds), yet systematic validation of Rotterdam criteria's 12-follicle threshold has not been conducted across these distinct populations to establish ethnicity-specific diagnostic criteria.

• Deep learning-based multimodal prediction of chronic kidney disease stage (2026) · doi

  The multimodal deep learning model achieves 97.9% accuracy on the current dataset, but the paper does not evaluate model performance on external validation cohorts or datasets from different clinical centers. Generalization of the CKD stage prediction model across diverse patient populations and healthcare systems with potentially different laboratory measurement standards remains unvalidated.

• Effectiveness of screening modalities for early detection of diabetic retinopathy: a systematic review and meta-analysis of tele-ophthalmology, AI-based tools, and conventional methods (2026) · doi

  Handheld fundus camera DR screening shows variable image quality and has only been evaluated in single healthcare systems; standardized protocols for handheld camera-based DR detection with quality assurance thresholds across diverse clinical settings require development.

• The Relationship between a History of Cesarean Section and The Incidence of Placenta Accreta : A Systematic Review (2026) · doi

  Isthmocele presence on ultrasound appears to correlate with disproportionately higher PAS risk, but this relationship has only been characterized in a single case series (Marbin et al.). Prospective studies measuring isthmocele dimensions, depth, and morphology against accreta incidence across multiple centers are required to establish whether scar niche parameters can serve as direct predictors independent of CS number.

• A systematic review of sample size determination in Bayesian randomized clinical trials: full Bayesian methods are rarely used (2026) · doi

  The review documents extensive use of hybrid approaches across diverse outcome types (binary, continuous, ordinal, survival, joint, count, multiple endpoints), but does not systematically compare the performance or appropriateness of hybrid versus full Bayesian sample size methods across these specific outcome data structures. Research is needed to establish when hybrid methods are justified versus when full Bayesian approaches would be superior for each outcome type.

• Unveiling the relationship of the comorbidity between depression and type 2 diabetes mellitus: a macro analysis and micro interpretation (2026) · doi

  The reciprocal intervention model for depression and T2DM comorbidity—regulating metabolic status through psychological intervention or alleviating emotional disorders through blood glucose control—requires high-quality evidence through cross-border collaborative trials. Specific clinical trial designs testing this bidirectional treatment approach across different healthcare systems remain underdeveloped.

• A behaviour and disease model of testing and isolation (2026) · doi

  The model implements idealised testing conditions with no delays in test accessibility, availability, or supply constraints. Future modelling should incorporate empirical data on test supply limitations and investigate the cascading effects on infectious prevalence when individuals cannot access tests and do not self-isolate, as well as the negative feedbacks on testing uptake for future infection episodes.

• Bioactive and Ion-releasing materials in minimum intervention dentistry: a clinical pathway from prevention to restorative treatment (2026) · doi

  Long-term randomised clinical trials comparing ion-releasing bioactive restorative materials (calcium, phosphate, fluoride, zinc, magnesium, silanols) are needed to test superiority in clinical outcomes such as tooth survival, secondary caries incidence, postoperative hypersensitivity, and restoration longevity using S3-level evidence-based guideline methodology.

• Treatment options for long head of biceps tendon tenodesis (2026) · doi

  The novel double 360° lasso-loop fixation technique for long head of biceps tendon tenodesis lacks long-term clinical and biomechanical studies to evaluate its reliability and durability beyond short- to mid-term follow-up periods. Specific investigations are needed comparing failure rates, cyclic displacement, and gap formation of this technique against established fixation methods over extended timeframes.

• Artificial intelligence approaches to predicting treatment non-adherence in chronic diseases: a narrative review (2026) · doi

  Most adherence prediction literature terminates at machine learning model development rather than conducting prospective clinical trials to demonstrate actual impact on patient medication adherence or clinical disease control outcomes. This methodological-to-implementation gap prevents validation of whether AI-based adherence prediction models meaningfully improve treatment adherence rates in real clinical workflows.

• Evidence-based approaches for Empty Nose Syndrome management: a systematic review highlighting current treatments and future directions (2026) · doi

  Outcome measures for Empty Nose Syndrome management are not consistently defined, validated, or reliably applied across studies, creating heterogeneity that hinders comparison of surgical, regenerative, and pharmacological-cognitive treatment efficacy across different patient populations.

• Human-centered Perspectives on a Clinical Decision Support System for Intensive Outpatient Veteran PTSD Care (2026) · doi

  Future CDSS design for veteran PTSD care must explicitly incorporate and evaluate patient privacy, data security, and trust factors in the context of passive tracking of health data and sPGD (standardized patient-generated data). The ethical implications of implementing these tracking mechanisms within a clinical decision support system for manualized psychotherapy have not been empirically tested with veteran populations.

• Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review) (2026) · doi

  Multimodal AI for diagnosis of clinically significant prostate cancer has been evaluated in multicenter studies (reference 57), but longitudinal validation of AI-derived predictions against long-term biochemical recurrence, metastasis-free survival, and castration resistance endpoints in independent prospective cohorts is absent.

• GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders (2026) · doi

  Clinical translation of GlyT1 inhibition efficacy from preclinical models (rats and monkeys) to human trials remains incomplete. Optimal dosing regimens, long-term safety profiles, and efficacy across diverse populations for schizophrenia, cerebral ischemia, Alzheimer's disease, and addiction disorders have not been fully established in rigorous clinical settings.

• Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers (2026) · doi

  While quercetin liposomes, phytosomes, nanoemulsions, and hydrogel delivery systems have been individually evaluated for improved bioavailability in metabolic disease models, comparative efficacy studies directly contrasting these nanoencapsulation approaches in the same diabetic or obesity cohorts are absent. Head-to-head comparison of succinyl chitosan-stabilized liposomes versus whey protein isolate hydrogels versus lecithin phytosomes in streptozotocin-induced or db/db diabetic models is needed to establish which delivery system optimizes quercetin bioavailability and therapeutic outcomes.

• Lipidomics and machine learning revealing dysregulation of specific triacylglycerol and phosphatidylglycerol as hub lipids associated with fetal growth in gestational diabetes mellitus (2026) · doi

  The LogitBoost-based lipidomic signature model (AUC = 0.904) for GDM detection requires validation in larger, independent cohorts beyond the current dataset to establish generalizability and diagnostic accuracy across diverse pregnant populations and different geographic regions.